....Insmed doesn't meet primary endpoint and gets clobbered today. July 1, 2013, Insmed meets Primary endpoint and gets clobbered. Hmmmmm......confusing, what??
Here is the headline from July 1st
ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
Perhaps there are one or two professional investors out there who know it's far easier to persuade retail shareholders to part with seriously-undervalued shares than it is to acquire them from other professional investors who understand valuation.